Cellivery Achieves Production Success of iCP-NI Capsule Formulation for Intractable Autoimmune Disease Crohn's Disease Treatment

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 20th that the capsule-type iCP-NI, being developed as a new drug for the treatment of the autoimmune disease Crohn's disease (Chron’s disease: CD), has entered efficacy evaluation testing at the contract testing organization IBD.

Crohn's disease is an autoimmune disease primarily caused by excessive inflammatory cytokines resulting from abnormal immune responses in the body. It is characterized by affecting the entire gastrointestinal tract. Major symptoms include abdominal pain, diarrhea, and anal pain, and in severe cases, intestinal resection surgery is required due to intestinal strictures (narrowing of the intestines) and intestinal perforations (holes in the intestines). The disease repeatedly cycles through recovery and relapse, lowering quality of life. According to the company, treatment is very difficult because long-term administration of temporary symptom relievers such as steroids, which can disrupt the immune system, is necessary.

Dr. Jaehyun Kim, Head of Autoimmune Disease Drug Development at Cellivery, stated, "iCP-NI restored 71% of congestion caused by edema, ulceration due to tissue depression, and bloody stools caused by hemorrhage in the colon tissue of Crohn's disease animal models, and reduced inflammatory immune T cells by 60%. It controlled the major pro-inflammatory cytokines that induce Crohn's disease?TNF-alpha (TNF-α), interleukin-6 (IL-6), and interferon-gamma (IFN-γ)?by 64%, 72%, and 97%, respectively, demonstrating its potential as a new drug for Crohn's disease treatment."

Daewoong Cho, CEO of Cellivery, said, "iCP-NI has completed development as an anti-inflammatory pharmacological substance in the United States and is currently on the verge of entering clinical development. In the Crohn's disease efficacy evaluation test conducted to change the formulation and expand indications, excellent therapeutic efficacy was proven, and efficacy evaluation testing is currently underway with the oral capsule formulation at a specialized contract analysis organization in France."

He added, "The successful development and production of the capsule formulation of iCP-NI is expected to improve patient convenience for Crohn's disease and maximize therapeutic effects through strong anti-inflammatory control. Given the current lack of specific treatments, we have high expectations for early clinical development and commercialization."